If they now proceed to the second cohort shouldn't that indicate that the pill did release Brilacidin in the correct part of the colon dealing with UC? That would be a major step in the right direction since then we only would have to worry about efficacy in the P2 trial assuming that the physiokinetic results all come back positive.

On the opposite side, if the first cohort doesn't release B at the right point what is the need to proceed to the 2nd and 3rd cohorts?